Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
Fund managers haven’t disclosed any holdings of SVA yet.
SVA Hedge Fund Activity: Q1 2026 in Review
28 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2026, worth a combined $225M — down 0.18% from $225M a quarter earlier.
Fund positioning in SVA was balanced in Q1 2026: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Harbour Investments, opening a new position worth an estimated $542. The largest seller was Aprio Wealth Management, exiting entirely with an estimated $284K sold.
- 28 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $225M of Sinovac Biotech, Ltd stock for Q1 2026, down 0.18% quarter-over-quarter.
- 3 funds opened new Sinovac Biotech, Ltd positions in Q1 2026 and 3 closed out, a net change of 0 holders.
- The largest Sinovac Biotech, Ltd buyer in Q1 2026 was Harbour Investments, an estimated $542 added.
- The largest Sinovac Biotech, Ltd seller in Q1 2026 was Aprio Wealth Management, an estimated $284K sold.
Based on aggregated 13F filings for Q1 2026.